Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Polycythemia vera is a rare, chronic disorder involving the overproduction of blood cells in the bone marrow (myeloproliferation). The overproduction of red blood cells is most changing, but the production of white blood cells and platelets are also elevated in most cases. Since red blood cells are overproduced in the marrow, this leads to abnormally high numbers of circulating red blood cells within the blood. Consequently, the blood thickens and increases in volume, a condition called hyperviscosity. Thickened blood may not flow through smaller blood vessels properly. A variety of symptoms can occur in individuals with polycythemia vera including nonspecific symptoms such as headaches, fatigue, weakness, dizziness or itchy skin, an enlarged spleen (splenomegaly), a variety of gastrointestinal issues and the risk of blood clot formation, which may prevent blood flow to vital organs such as heart, lungs, kidneys.

The global polycythemia vera therapeutics market is estimated to be valued at US$ 1,115.9 million in 2021 and is expected to exhibit a CAGR of 4.5% over the forecast period (2021-2028).

Figure 1. Global Polycythemia Vera Therapeutics Market Share (%), By Region, 2021

Polycythemia Vera Therapeutics  | Coherent Market Insights

The increasing incidence of polycythemia vera is expected to drive the growth of the global polycythemia vera therapeutics market over the forecast period.

For instance, according to the article in journal of Multidisciplinary Digital Publishing Institute (MDPI) in July 2020, the estimated annual incidence rates for polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis are 0.84, 1.03, and 0.47 per 100,000 population globally and the prevalence is much higher, particularly for PV and ET, as mortality rates are relatively low globally.

Furthermore, according to the National Organization for Rare Disorders, around 44 to 57 per 100,000 people in the U.S. are suffering from polycythemia vera.

Moreover, symptoms of polycythemia vera usually develop slowly over many years in patients. Often, the disorder is found incidentally on a blood test, as part of a routine exam before noticeable symptoms occur. Occasionally, affected individuals may report vague, nonspecific symptoms that eventually lead to diagnosis of the disorder. Several individuals with polycythemia vera slowly develop a variety of general, nonspecific symptoms that are common to many disorders such as headaches, fatigue, weakness, dizziness, excessive sweating especially at night, and itchy skin that, in severe cases, may be worse after taking a shower or a warm bath.

request-sample

Polycythemia Vera Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2019: US$ 1,115.9 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2028
Forecast Period 2021 to 2028 CAGR: 4.5% 2028 Value Projection: US$ 1,516.5 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Disease Type: Primary Polycythemia Vera, Secondary Polycythemia Vera
  • By Drug Class: Antimetabolite, Kinase Inhibitors, Alpha Interferon, Selective Serotonin Reuptake Inhibitors, Others
  • By Route of Administration: Oral, Intravenous, Intramuscular, Subcutaneous
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Pfizer Inc., Galena Biopharma, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, PharmaEssentia Corporation, Bayer AG, Mylan N.V., Teva Pharmaceuticals Industries Ltd, GlaxosmithKline plc, ANP Technologies, INC., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc, Karus Therapeutics Limited, and Miragen Therapeutics, Inc.

Growth Drivers:
  • Increasing incidence of polycythemia vera 
  • Increasing research and development activities for the development of novel therapeutics for the treatment of polycythemia vera
Restraints & Challenges:
  • Strict pricing and reimbursement policies 
  • Extremely high cost of drugs

Figure 2. Global Polycythemia Vera Therapeutics Market Value (US$ Mn), By Drug Class, 2021

Polycythemia Vera Therapeutics  | Coherent Market Insights

The increasing research and development activities for the development of novel therapeutics for the treatment of polycythemia vera is expected to drive the market growth over the forecast period.

Key players operating in the market are focusing on submitting application for approval of drugs therapy for the treatment of polycythemia vera, which is expected to drive growth of the global polycythemia vera therapeutics market over the forecast period.

For instance, in May 2021, PharmaEssentia USA Corporation, a subsidiary of Taiwan-based PharmaEssentia Corp., a global biopharmaceutical innovator company, announced the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), seeking approval for ropeginterferon alfa-2b-njft for the treatment of polycythemia vera (PV). The resubmission follows receipt of a complete response letter in March 2021, in which the U.S. FDA sought additional information regarding the administration format with the product. Importantly, no concerns were raised regarding the clinical profile of the product. Morever, noted were COVID-related restrictions that delayed the required pre-approval inspection of the company’s manufacturing facility in Taiwan.

Ropeginterferon alfa-2b-njft has orphan drug designation for the treatment of PV in the U.S. is marketed as Besremi in Europe. The product was approved by the European Medicines Agency (EMA) in 2019. The Ropeginterferon alfa-2b-njft molecule was invented and is manufactured by PharmaEssentia.

Furthermore, on June 3, 2021, Protagonist Therapeutics, a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its lead investigational new drug candidate, rusfertide, for the treatment of patients with polycythemia vera (PV) for the reduction of erythrocytosis in those patients, who do not require further treatment for thrombocytosis and/or leukocytosis.

Global Polycythemia Vera Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic

During this Covid-19 pandemic, pharmaceutical business, clinical tool companies and likewise biotechnology firms are facing difficulties that are occurring from the interruption in supply chains and the demand to transform service processes. As the researches reveal that there is no relationship in between blood cancer cells as well as coronavirus, hence polycythemia vera therapy market is being affected by the pandemic. If Covid-19 pandemic proceeds for a medium/long duration, it may impact the supply of product and also active ingredients around the world along with the import as well as export of drugs. There has been a disturbance in the treatment market. As coronavirus has actually ended up being the major emphasis on polycythemia vera therapeutics market and all study institutes, biotech as well as pharmaceutical companies are selected in cooperation job to manage Covid-19, who are previously engaged in research and development of therapeutics for the treatment of polycythemia vera.

Global Polycythemia Vera Therapeutics Market Restraint

The strict pricing and reimbursement policies, very high cost of drugs used in the treatment of polycythemia vera are the factors that are expected to hinder growth of the global polycythemia vera therapeutics market over the forecast period.

Key Players

Major players operating in the global polycythemia vera therapeutics market include Pfizer Inc., Galena Biopharma, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, PharmaEssentia Corporation, Bayer AG, Mylan N.V., Teva Pharmaceuticals Industries Ltd, GlaxosmithKline plc, ANP Technologies, INC., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc, Karus Therapeutics Limited, and Miragen Therapeutics, Inc.

Polycythemia vera is a blood disorder in which the body creates too many red blood cells. These extra red cells make blood thicker than normal. The thickened blood flows slower and may clot within body. Red blood cells carry oxygen to organs and tissues throughout the body. If the blood moves too slowly or clots, the cells cannot deliver enough oxygen. This situation can cause serious complications including heart attack, stroke, and heart failure. There are two types of polycythemia vera, which include primary polycythemia vera and secondary polycythemia vera. Polycythemia vera gets worse with time if remain undiagnosed and can be life-threatening. Polycythemia vera can be treatable but is not curable. Polycythemia vera treatment may include phlebotomy and drug therapy. Phlebotomy involves the removal of blood from the body. Drug therapy involves the use of Hydroxyurea and Interferon-alfa. Patients who do not respond to hydroxyurea are treated with ruxolitinib (jakafi) or busulfan. At times a low dose of aspirin, allopurinol and antihistamines are also preferred for polycythemia vera treatment. Givinostat is an emerging drug in global polycythemia vera treatment market.

Market Dynamics

The increasing incidence of polycythemia vera, rising research and development activities for the development of novel therapeutics for the treatment of polycythemia vera, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global polycythemia vera therapeutics market over the forecast period.

For instance, according to the National Organization for Rare Disorders, polycythemia vera affects slightly more men than women and the disorder is estimated to affect around 44 to 57 per 100,000 people in the U.S. each year It occurs most often in individuals over 60 years old, but can affect individuals of any age. It is extremely rare in individuals under the age of 20.

Key features of the study:

  • This report provides in-depth analysis of the global polycythemia vera therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global polycythemia vera therapeutics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Pfizer Inc, Galena Biopharma, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, PharmaEssentia Corporation, Bayer AG, Mylan N.V., Teva Pharmaceuticals Industries Ltd, GlaxosmithKline plc, ANP Technologies, INC., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc, Karus Therapeutics Limited, and Miragen Therapeutics, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global polycythemia vera therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global polycythemia vera therapeutics market

Detailed Segmentation:

  • Global Polycythemia Vera Therapeutics Market, By Disease Type:
    • Primary Polycythemia Vera
    • Secondary Polycythemia Vera
  • Global Polycythemia Vera Therapeutics Market, By Drug Class:
    • Antimetabolite
    • Kinase Inhibitors
    • Alpha Interferon
    • Selective Serotonin Reuptake Inhibitors
    • Others
  • Global Polycythemia Vera Therapeutics Market, By Route of Administration:
    • Oral
    • Intravenous
    • Intramuscular
    • Subcutaneous
  • Global Polycythemia Vera Therapeutics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Polycythemia Vera Therapeutics Market, By Region:
    • North America
      • By Disease Type
        • Primary Polycythemia Vera
        • Secondary Polycythemia Vera
      • By Drug Class
        • Antimetabolite
        • Kinase Inhibitors
        • Alpha Interferon
        • Selective Serotonin Reuptake Inhibitors
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Intramuscular
        • Subcutaneous
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Disease Type
        • Primary Polycythemia Vera
        • Secondary Polycythemia Vera
      • By Drug Class
        • Antimetabolite
        • Kinase Inhibitors
        • Alpha Interferon
        • Selective Serotonin Reuptake Inhibitors
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Intramuscular
        • Subcutaneous
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Disease Type
        • Primary Polycythemia Vera
        • Secondary Polycythemia Vera
      • By Drug Class
        • Antimetabolite
        • Kinase Inhibitors
        • Alpha Interferon
        • Selective Serotonin Reuptake Inhibitors
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Intramuscular
        • Subcutaneous
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Disease Type
        • Primary Polycythemia Vera
        • Secondary Polycythemia Vera
      • By Drug Class
        • Antimetabolite
        • Kinase Inhibitors
        • Alpha Interferon
        • Selective Serotonin Reuptake Inhibitors
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Intramuscular
        • Subcutaneous
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Disease Type
        • Primary Polycythemia Vera
        • Secondary Polycythemia Vera
      • By Drug Class
        • Antimetabolite
        • Kinase Inhibitors
        • Alpha Interferon
        • Selective Serotonin Reuptake Inhibitors
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Intramuscular
        • Subcutaneous
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Disease Type
        • Primary Polycythemia Vera
        • Secondary Polycythemia Vera
      • By Drug Class
        • Antimetabolite
        • Kinase Inhibitors
        • Alpha Interferon
        • Selective Serotonin Reuptake Inhibitors
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Intramuscular
        • Subcutaneous
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Pfizer Inc *
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Galena Biopharma
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Eli Lilly and Company
    • PharmaEssentia Corporation
    • Bayer AG
    • Mylan N.V.
    • Teva Pharmaceuticals Industries Ltd
    • GlaxosmithKline plc
    • ANP Technologies, INC.
    • Hoffmann-La Roche Ltd.
    • Gilead Sciences, Inc
    • Karus Therapeutics Limited
    • Miragen Therapeutics, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Disease Type
      • Market Snippet, By Drug Class
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • PEST Analysis
    • Regulatory Scenario
    • Market Trends
    • Key Highlights
    • Reimbursement Scenario
    • Mergers & Acquisitions
  4. Global Polycythemia Vera Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic
    • Economic Impact
    • Impact on Clinical Trials and Drug Development
    • Government Initiatives
  5. Global Polycythemia Vera Therapeutics Market, By Disease Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Primary Polycythemia Vera
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Secondary Polycythemia Vera
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  6. Global Polycythemia Vera Therapeutics Market, By Drug Class, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Antimetabolite
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Kinase Inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Alpha Interferon
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Selective Serotonin Reuptake Inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  7. Global Polycythemia Vera Therapeutics Market, By Route of Administration, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Intravenous
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Intramascular
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Subcutaneous
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  8. Global Polycythemia Vera Therapeutics Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  9. Global Polycythemia Vera Therapeutics Market, By Region, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018–2028
    • North America
      • Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Region/Country, 2017 – 2028, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  10. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Galena Biopharma
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bristol-Myers Squibb Company
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • PharmaEssentia Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Mylan N.V.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Teva Pharmaceuticals Industries Ltd
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GlaxosmithKline plc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • ANP Technologies, INC.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Hoffmann-La Roche Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Gilead Sciences, Inc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Karus Therapeutics Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Miragen Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  11. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 44 market data tables and 38 figures on "Polycythemia Vera Therapeutics Market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The global polycythemia vera therapeutics market size is estimated to be valued at US$ 1,115.9 million in 2021 and is expected to exhibit a CAGR of 4.5% between 2021 and 2028.
Increasing incidence of polycythemia vera and increasing research and development activities for the development of novel therapeutics for the treatment of polycythemia vera are expected to drive the market growth over the forecast period.
Kinase inhibitors segment is expected to hold the major market share, owing to increasing product approvals and launches during the forecast period.
North America holds the largest market share in the market.
Major factors hampering growth of the market include the strict pricing and reimbursement policies, and extremely high cost of drugs.
Major players operating in the market include Pfizer Inc., Galena Biopharma, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, PharmaEssentia Corporation, Bayer AG, Mylan N.V., Teva Pharmaceuticals Industries Ltd, GlaxosmithKline plc, ANP Technologies, INC., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc, Karus Therapeutics Limited, and Miragen Therapeutics, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.